Sort   by:  
 Page size 
TranscriptomicsBlood mRNA expression signatures derived from unsupervised analyses identify prostate cancers with poor outcome
Background: Inter-patient prostate cancer (PrCa) heterogeneity results in highly variable patient outcomes. Multi-purpose biomarkers to dissect this heterogeneity are urgently required to improve treatment and accelerate drug development in PrCa. Circulating biomarkers are most practical for evaluat...
ORGANISM(S): Homo sapiens 
2012-10-15 | E-GEOD-37199 | biostudies-arrayexpress
TranscriptomicssiRNA knockdown of ribosomal protein gene RPL19 abrogates the aggressive phenotype of human prostate cancer
Ribosomal protein RPL19 is an integral component of eukaryotic ribosomes and universally involved in protein synthesis. Although consistently stableM-BM- in normal cells, RPL19 transcription is relatively elevated in prostate cancer. Using siRNA, we inhibited RPL19 transcription and demonstrated th...
ORGANISM(S): Homo sapiens 
2011-12-08 | E-GEOD-26774 | biostudies-arrayexpress
MetabolomicsMetabolomic profiling of Fraxinus excelsior genotypes tolerant or susceptible to ash dieback disease reveals changes in iridoid glycosides
European common ash, Fraxinus excelsior L., is currently threatened by Ash dieback (ADB) caused by the fungus, Hymenoscyphus fraxineus. To detect and identify metabolites that may be products of pathways important in contributing to resistance against H. fraxineus we performed untargeted metabolomic...
2016-11-09 | MTBLS372 | MetaboLights
TranscriptomicsA transcriptional signature of fatigue derived from patients with primary Sjögren's Syndrome
Fatigue is a debilitating condition with a significant impact on patients’ quality of life. Fatigue is frequently reported by patients suffering from primary Sjo ̈gren’s Syndrome (pSS), a chronic autoimmune condition characterised by dryness of the eyes and the mouth. However, although fatigue ...
ORGANISM(S): Homo sapiens 
2015-12-31 | E-GEOD-66795 | biostudies-arrayexpress
UnknownMetformin for patients with metastatic prostate cancer starting androgen deprivation therapy: a randomised phase 3 trial of the STAMPEDE platform protocol.
Not available
S-EPMC12303861 | biostudies-literature
Sort   by:  
 Page size